CLINICAL TRIAL PROTOCOL: Diabetes Management Study

TITLE: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XYZ-Drug in Adult Patients with Type 2 Diabetes Mellitus

STUDY OBJECTIVES:
Primary: To evaluate the efficacy of XYZ-Drug in reducing HbA1c levels in patients with Type 2 diabetes mellitus.

ELIGIBILITY CRITERIA:

INCLUSION CRITERIA:
1. Male or female patients aged 18 to 65 years
2. Diagnosed with Type 2 diabetes mellitus for at least 6 months
3. HbA1c levels between 7.0% and 10.5%
4. Body Mass Index (BMI) between 25 and 40 kg/m²
5. Stable on metformin therapy for at least 3 months prior to screening
6. Willing and able to provide informed consent

EXCLUSION CRITERIA:
1. Type 1 diabetes mellitus or secondary forms of diabetes
2. History of diabetic ketoacidosis or hyperosmolar hyperglycemic state
3. Severe cardiovascular disease including myocardial infarction within 6 months
4. Severe renal impairment (eGFR < 30 mL/min/1.73m²)
5. Active liver disease or ALT/AST > 3x upper limit of normal
6. Pregnancy or breastfeeding
7. Current use of insulin or other antidiabetic medications except metformin
8. History of pancreatitis
9. Active malignancy within the past 5 years
10. Current smokers or those who quit smoking less than 6 months ago

STUDY DESIGN:
This is a 24-week, randomized, double-blind, placebo-controlled study. Approximately 200 patients will be randomized in a 1:1 ratio to receive either XYZ-Drug or placebo.
